Elevara Medicines raises $70 Million Series A funding co-led by Forbion and Sofinnova Partners to advance ELV001 for rheumatoid arthritis treatments.

Oct 22, 2025•4 days ago

Amount Raised

$70 Million

Round Type

series a

LondonBiotechnologyHealth Care

Investors

Monograph CapitalSofinnova PartnersForbion

Description

Elevara Medicines announced a $70 million Series A financing round co-led by Forbion and Sofinnova Partners. The funding will support the Phase 2 clinical trial of their lead candidate ELV001 and exploratory programs in other conditions. This series aims to address inadequate responses in patients with rheumatoid arthritis. Recruitment for the trial is expected to begin before the end of 2025.

Company Information

Company

Elevara Medicines

Location

London, England, United Kingdom

About

Elevara Medicines is a clinical-stage biotech company focused on developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases. The company's lead program, ELV001, is an innovative oral CDK4/6 inhibitor that targets synovial fibroblasts, aiming to disrupt traditional treatment paradigms. Elevara's goal is to provide effective options for patients who do not achieve disease remission with current immune-targeted therapies. The company collaborates with various investors and has exclusive rights to develop ELV001 from Teijin Pharma.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends